Conference abstractPublished 2015
Activity of nanoparticulate tetrac (nanotetrac) on models of glioblastoma
Albany College of Pharmacy and Health Sciences, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Glioblastoma multiforme (GBM) is an aggressive brain tumor with a less than 10% 5-year survival rate. The tumor is relatively chemo- and radioresistant and, despite its vascularity, has shown disappointing clinical responses to antiangiogenic management. Nanoparticulate tetrac (Nanotetrac) is anti-cancer/anti-angiogenic agent that acts exclusively at a thyroid hormone-tetrac receptor on plasma membrane integrin αvβ3 and does not gain entry to cells. In the formulation, tetrac is covalently bound via a linker to poly(lactic-co-glycolic acid) (PLGA) nanoparticles. From the integrin, the agent disorders a panel of tumor cell defense pathways by downstream actions on expression of differentially regulated genes and is pro-apoptotic by several mechanisms. In the C6 rat subcutaneous glioma xenograft in the mouse, standard clinical GBM chemotherapy with temozolomide (TMZ) at 10 mg/kg was wholly ineffective (tumor volumes) at 14 d, as was subtherapeutic Nanotetrac at 0.3 mg/kg. Added to TMZ, Nanotetrac at 0.3 mg/kg reduced tumor volume by 53% at 14 d. In the subcutaneous human U87MG (U87-luc) GBM xenograft, Nanotetrac at 1 mg/kg injected with implanted cells inhibited tumor growth by 79% at 16 d. Luminescent scanning revealed no viable cells in the Nanotetrac-exposed tumors, with full viability in the void PLGA-injected lesions. Systemic (s.c.) Nanotetrac at 1 mg/kg reduced subcutaneous tumor U87MG xenograft volume by 46% at 10 d. All Nanotetrac results were significant at p <0.05. Studied in vitro, U87MG cells proliferated in response to physiological concentrations of free L-thyroxine (T4) and supraphysiological levels of 3,5,3,-triiodo-L-thyronine (T3). The T4 effect was associated with activation of mitogen-activated protein kinase (pERK1/2), but not phosphatidylinositol 3-kinase. Taken together, these studies indicate that 1) GBM is a thyroid hormone-responsive tumor, consistent with clinical observations of the action of induced hypothyroxinemia on GBM and 2) Nanotetrac systemically or intratumorally is effective in reducing GBM xenograft volumes/weights and reducing tumor cell viability.
Subjects
EngineeringAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Regenerative Medicine
- SubjectEngineering
- BylineArticles whose byline prints “Paul J Davis”
- BylineArticles whose byline prints “Shaker A Mousa”
